domenica, 3 maggio 2026

Notizie AIOM – anno XV

1 Dicembre 2017

FDA Approves FoundationOne CDx, CMS Agrees to Cover

November 30, 2017 - The FDA has approved the FoundationOne CDx (F1CDx) cancer biomarker assay concurrently with a decision from the Centers for Medicare & Medicaid Services (CMS) to provide insurance coverage for the next-generation sequencing (NGS)-based in vitro diagnostic ...
Leggi tutto

1 Dicembre 2017

Statement from FDA Commissioner Scott Gottlieb, M.D., on the approval of a new formulation of buprenorphine and FDA’s efforts to promote more widespread innovation and access to opioid addiction treatments

November 30, 2017 - With the approval today of a monthly formulation of the drug buprenorphine for the treatment of opioid use disorder, patients have access to a new and longer-acting option for the treatment of opioid addiction. Millions of Americans are suffering from ...
Leggi tutto

1 Dicembre 2017

Web-app

Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore dell’ovaio è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due ...
Leggi tutto

28 Novembre 2017

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-). Eligible patients ...
Leggi tutto

24 Novembre 2017

Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval

November 21, 2017 - The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non–small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation. The agency is reviewing ...
Leggi tutto

24 Novembre 2017

Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults

Mismatch repair (MMR) deficiency of DNA has been observed in up to 15% of sporadic colorectal cancers (CRCs) and is a characteristic feature of Lynch syndrome, which has a higher incidence in young adults (age,

24 Novembre 2017

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naïve prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE. No data are available on the efficacy of treatments used for metastatic ...
Leggi tutto

24 Novembre 2017

Nilotinib Approved in Europe for Subset of Pediatric CML

November 20, 2017 - The European Commission (EC) has approved nilotinib for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP), both in the frontline setting and for those with resistance ...
Leggi tutto

24 Novembre 2017

EU Approves Abiraterone for Newly Diagnosed Hormone-Sensitive Prostate Cancer

November 20, 2017 - The European Commission (EC) has approved abiraterone acetate in combination with prednisone/prednisolone for the treatment of adult men with newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation ...
Leggi tutto

24 Novembre 2017

20 novembre 2017 – Sicurezza dei medicinali: anche quest’anno AIFA aderisce alla campagna social europea sulla segnalazione delle sospette reazioni avverse